Results 281 to 290 of about 79,600 (335)

A surrogate endpoint

2023
In Chapter 3, I utilize publicly available datasets of gene expression and DNA methylation in sarcomas to interrogate PRC2-dependent mechanisms of epigenetic crosstalk. I have shown that loss of PRC2 correlates with a global hypermethylation profile, tumor microenvironment changes, and patient outcome.
openaire   +1 more source

Surrogate Endpoints in Suicide Research

Suicide and Life-Threatening Behavior, 2010
Surrogate endpoints frequently substitute for rare outcomes in research. The ability to learn about completed suicides by investigating more readily available and proximate outcomes, such as suicide attempts, has obvious appeal. However, concerns with surrogates from the statistical science perspective exist, and mounting evidence from psychometric ...
Hal S, Wortzel, Peter M, Gutierrez, Beeta Y, Homaifar, Ryan E, Breshears, Jeri E, Harwood   +4 more
openaire   +2 more sources

The Evaluation of Multiple Surrogate Endpoints

Biometrics, 2001
Summary.Surrogate endpoints are desirable because they typically result in smaller, faster efficacy studies compared with the ones using the clinical endpoints. Research on surrogate endpoints has received substantial attention lately, but most investigations have focused on the validity of using a single biomarker as a surrogate.
Xu, Jane, Zeger, Scott L.
openaire   +2 more sources

Validating Surrogate Endpoints

2013
The International Conference of Harmonisation (ICH) Guideline E9, Statistics Principles for Clinical Trials, recommends that surrogate endpoints in clinical trials be validated using either (1) the sensitivity-specificity approach or (2) regression analysis.
Ton J. Cleophas, Aeilko H. Zwinderman
openaire   +1 more source

Surrogate Endpoints of Clinical Benefit

2012
Despite several decades of intensive clinical and biological research and significant progress in primary prevention, screening, diagnosis, prognosis, and treatment, cancer is still the second most common cause of death in developed countries, accounting for about one-fourth of total deaths [1].
G. Ciccone, BALDI, ILEANA
openaire   +2 more sources

[Surrogate endpoints].

Bulletin du cancer, 1999
The main endpoint of a phase III trial in oncology must be relevant clinically. In practice, this endpoint is either the disease-free or the overall survival, which requires both long term follow-up and a large number of patients. In phase II trials, it is essential to proceed rapidly, and one therefore uses a surrogate endpoint.
openaire   +1 more source

Clinical trials: surrogate endpoints or hard endpoints?

The American Journal of Cardiology, 2001
A man, aged 50, has about a 50% risk and a 50-year-old woman a 35% risk of having a myocardial infarction during their lifetime. The extent of atherosclerosis is the primary determinant of the risk of myocardial infarction. We will be unable to substantially reduce the lifetime risk of coronary artery disease without primary prevention of ...
openaire   +2 more sources

Endpoints: Surrogates and Composites

Cardiovascular Revascularization Medicine, 2022
openaire   +2 more sources

Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease.

Nutrition reviews, 2008
This article reviews surrogate endpoints and emerging biomarkers that were discussed at the annual "Cardiovascular Biomarkers and Surrogate Endpoints" symposium cosponsored by the US Food and Drug Administration (FDA) and the Montreal Heart Institute.
Crystal M, Rasnake, Paula R, Trumbo, Therese M, Heinonen   +2 more
openaire   +1 more source

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

Nature Medicine, 2023
Lesley A Inker, Fernando Caravaca-Fontan, Tazeen Hasan Jafar   +2 more
exaly